Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nextcure Inc.

0.6889
-0.0311-4.32%
Post-market: 0.68890.00000.00%16:51 EDT
Volume:15.11K
Turnover:10.66K
Market Cap:19.29M
PE:-0.35
High:0.7298
Open:0.7200
Low:0.6841
Close:0.7200
Loading ...

Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles

TIPRANKS
·
08 Mar

NextCure Price Target Cut to $3.00/Share From $4.00 by HC Wainwright & Co.

Dow Jones
·
07 Mar

NextCure FY 2024 GAAP EPS $(1.99) Misses $(1.92) Estimate

Benzinga
·
07 Mar

BRIEF-NextCure FY Net Income USD -55.654 Million

Reuters
·
07 Mar

NextCure Inc: Expect Current Financial Resources to Fund Operating Expenses & Capex Into H2 2026

THOMSON REUTERS
·
07 Mar

NextCure FY Basic EPS USD -1.99

THOMSON REUTERS
·
07 Mar

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

GlobeNewswire
·
07 Mar

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?

Simply Wall St.
·
10 Feb

NextCure Announces First Patient Dosed in the Phase 1 Study of Lncb74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

THOMSON REUTERS
·
10 Jan

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

GlobeNewswire
·
10 Jan

NextCure Announces Acceptance of Ind Application for Lncb74

THOMSON REUTERS
·
10 Dec 2024

NextCure Announces Acceptance of IND Application for LNCB74

GlobeNewswire
·
10 Dec 2024

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC)

TIPRANKS
·
06 Dec 2024

NextCure announces preclinical data on NC605

TIPRANKS
·
19 Nov 2024

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

GlobeNewswire
·
19 Nov 2024

NextCure Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024